Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?

In worldwide clinical settings, several nucleos(t)ide analogues (NAs), including tenofovir disoproxil fumarate (TDF), entecavir (ETV), and tenofovir alafenamide fumarate (TAF) are used to treat patients chronically infected with HBV.1,2 NAs are easily administrated orally and have favorable pharmacologic profiles.3 Their use is generally preferred to that of the immune stimulator pegylated-interferon (Peg-IFN)-alpha, which induces more adverse effects (AEs) and less virological suppression (i.e.